Switch theme
Sign up to access all valuation multiples
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
1996
2.2K+
LTM Revenue $932M
LTM EBITDA $217M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genomma Lab has a last 12-month revenue of $932M and a last 12-month EBITDA of $217M.
In the most recent fiscal year, Genomma Lab achieved revenue of $918M and an EBITDA of $204M.
Genomma Lab expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genomma Lab valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $813M | $918M | XXX | XXX | XXX |
| Gross Profit | $502M | $498M | XXX | XXX | XXX |
| Gross Margin | 62% | 54% | XXX | XXX | XXX |
| EBITDA | $137M | $204M | XXX | XXX | XXX |
| EBITDA Margin | 17% | 22% | XXX | XXX | XXX |
| Net Profit | $68.6M | $53.5M | XXX | XXX | XXX |
| Net Margin | 8% | 6% | XXX | XXX | XXX |
| Net Debt | $241M | $233M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Genomma Lab's stock price is MXN 23 (or $1).
Genomma Lab has current market cap of MXN 21.6B (or $1.1B), and EV of MXN 25.7B (or $1.3B).
See Genomma Lab trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.1B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Genomma Lab has market cap of $1.1B and EV of $1.3B.
Genomma Lab's trades at 1.4x LTM EV/Revenue multiple, and 5.8x LTM EBITDA.
Analysts estimate Genomma Lab's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Genomma Lab and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 6.2x | XXX | XXX | XXX |
| P/E | 10.1x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | 9.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGenomma Lab's NTM/LTM revenue growth is 6%
Genomma Lab's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Genomma Lab's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Genomma Lab's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Genomma Lab and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 49% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 28% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 41% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 43% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genomma Lab acquired XXX companies to date.
Last acquisition by Genomma Lab was XXXXXXXX, XXXXX XXXXX XXXXXX . Genomma Lab acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Genomma Lab founded? | Genomma Lab was founded in 1996. |
| Where is Genomma Lab headquartered? | Genomma Lab is headquartered in Mexico. |
| How many employees does Genomma Lab have? | As of today, Genomma Lab has 2.2K+ employees. |
| Is Genomma Lab publicy listed? | Yes, Genomma Lab is a public company listed on MEX. |
| What is the stock symbol of Genomma Lab? | Genomma Lab trades under LABB ticker. |
| When did Genomma Lab go public? | Genomma Lab went public in 2008. |
| Who are competitors of Genomma Lab? | Similar companies to Genomma Lab include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Genomma Lab? | Genomma Lab's current market cap is $1.1B |
| What is the current revenue of Genomma Lab? | Genomma Lab's last 12-month revenue is $932M. |
| What is the current EBITDA of Genomma Lab? | Genomma Lab's last 12-month EBITDA is $217M. |
| What is the current EV/Revenue multiple of Genomma Lab? | Current revenue multiple of Genomma Lab is 1.4x. |
| What is the current EV/EBITDA multiple of Genomma Lab? | Current EBITDA multiple of Genomma Lab is 5.8x. |
| What is the current revenue growth of Genomma Lab? | Genomma Lab revenue growth between 2023 and 2024 was 13%. |
| Is Genomma Lab profitable? | Yes, Genomma Lab is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
